Literature DB >> 24202062

Parathyroid-hormone variance is only marginally explained by a panel of determinants: a cross-sectional study of 909 hip-fracture patients.

Marco Di Monaco1, Carlotta Castiglioni, Fulvia Vallero, Roberto Di Monaco, Rosa Tappero.   

Abstract

Several factors affect the levels of parathyroid hormone (PTH) in hip-fracture patients. We hypothesized that a panel of easily assessable determinants could account for both a substantial proportion of PTH variance and the occurrence of secondary hyperparathyroidism. We evaluated 909 of 981 hip-fracture inpatients admitted consecutively to our Rehabilitation division. In each patient we assessed PTH, 25-hydroxyvitamin D, albumin-adjusted total calcium, phosphate, magnesium, and creatinine on a fasting blood sample 21.3 ± 6.1 (mean ± SD) days after fracture occurrence. Glomerular filtration rate (GFR) was estimated by the 4-variable Modification of Diet in Renal Disease Study equation. Functional level was assessed using the Barthel index. On multivariate analysis, six factors (phosphate, albumin-adjusted total calcium, estimated GFR (eGFR), 25-hydroxyvitamin D, age, and magnesium) were significantly associated with PTH levels. Overall, the panel of variables accounted for 23.7 % of PTH variance. Among the 909 patients, 304 (33.4 %) had PTH levels exceeding the normal range. Six factors (phosphate, albumin-adjusted total calcium, eGFR, 25-hydroxyvitamin D, age, and Barthel index scores) were significantly associated with the category of PTH level (either normal or elevated). The model correctly classified 70.4 % of cases. For the optimal cut-off point, sensitivity was 80 % and specificity was 61 %. Data shows that six factors were significantly associated with PTH levels in hip-fracture inpatients. However, the six factors accounted for only 23.7 % of PTH variance and the presence or absence of secondary hyperparathyroidism was correctly categorized in a modest proportion of cases. We conclude that more knowledge is needed on the factors affecting PTH levels after hip fracture.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24202062     DOI: 10.1007/s00774-013-0532-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  43 in total

1.  Parathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women.

Authors:  J Y Reginster; I Frederick; R Deroisy; W Dewe; A N Taquet; A Albert; J Collette; H Pirenne; S X Zheng; C Gosset
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

3.  Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.

Authors:  Lourdes Craver; Maria Paz Marco; Isabel Martínez; Montserrat Rue; Merce Borràs; Maria Luisa Martín; Felipe Sarró; José Manuel Valdivielso; Elvira Fernández
Journal:  Nephrol Dial Transplant       Date:  2007-01-05       Impact factor: 5.992

4.  Hypovitaminosis D and secondary hyperparathyroidism in the elderly: risk factors for hip fracture or markers of frailty?

Authors:  A Barone; A Giusti; G Pioli
Journal:  Osteoporos Int       Date:  2007-05-25       Impact factor: 4.507

5.  Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study.

Authors:  Denise G von Mühlen; Gail A Greendale; Cedric F Garland; Lori Wan; Elizabeth Barrett-Connor
Journal:  Osteoporos Int       Date:  2005-06-01       Impact factor: 4.507

6.  Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.

Authors:  M C Chapuy; R Pamphile; E Paris; C Kempf; M Schlichting; S Arnaud; P Garnero; P J Meunier
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

Review 7.  Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.

Authors:  P Lips
Journal:  Endocr Rev       Date:  2001-08       Impact factor: 19.871

8.  Secondary hyperparathyroidism in patients from Western Australia with hip fracture: relationship to type of hip fracture, renal function, and vitamin D deficiency.

Authors:  D G Bruce; A St John; F Nicklason; P R Goldswain
Journal:  J Am Geriatr Soc       Date:  1999-03       Impact factor: 5.562

9.  Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone.

Authors:  Masahiro Yamamoto; Toru Yamaguchi; Mika Yamauchi; Shozo Yano; Toshitsugu Sugimoto
Journal:  J Bone Miner Metab       Date:  2011-05-19       Impact factor: 2.626

10.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

View more
  4 in total

1.  Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men.

Authors:  Emma O Billington; Greg D Gamble; Ian R Reid
Journal:  Bonekey Rep       Date:  2016-12-07

2.  Bone metabolism subgroups identified as hip fracture patients via clustering.

Authors:  Evangelia Papakitsou; Ioanna Paspati; Stavroula Rizou; George P Lyritis
Journal:  Hormones (Athens)       Date:  2021-02-23       Impact factor: 2.885

3.  Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes.

Authors:  Leon Fisher; Wichat Srikusalanukul; Alexander Fisher; Paul Smith
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

4.  Comprehensive assessment of tissue and serum parameters of bone metabolism in a series of orthopaedic patients.

Authors:  Jan Gunsser; Regina Hermann; Andreas Roth; Amelie Lupp
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.